Circulating miR-221/222 reduces CD4+ T cells by inhibiting CD4 expression in colorectal cancer

Area of Science:

• Molecular Biology
• Immunology
• Oncology

Background:

• Low CD4+ T cell counts are observed in many cancer patients, but the underlying molecular mechanisms remain largely unknown.
• Colorectal cancer (CRC) is a significant global health concern, necessitating improved diagnostic and therapeutic strategies.

Purpose of the Study:

• To investigate the role of microRNAs (miRNAs) in regulating CD4+ T cell levels in colorectal cancer.
• To identify potential circulating biomarkers for CRC diagnosis.
• To explore the therapeutic potential of targeting miRNA-mediated pathways in cancer immunotherapy.

Main Methods:

• Quantification of miR-221 and miR-222 levels in the peripheral blood of CRC patients and healthy controls.
• Transfection experiments in human primary T cells to assess the impact of miR-221/222 on CD4 and CD8 antigen expression.
• Luciferase reporter assays to confirm direct regulation of CD4 expression by miR-221/222.

Main Results:

• Circulating levels of miR-221 and miR-222 were significantly increased in patients with colorectal cancer (CRC).
• Both miR-221 and miR-222 demonstrated high diagnostic accuracy for CRC, with AUC values of 0.8790 and 0.9148, respectively.
• Overexpression of miR-221 or miR-222 led to a significant reduction in surface CD4 antigen levels in human primary T cells, without affecting CD8 antigen levels.
• Luciferase assays confirmed that miR-221 and miR-222 directly target and inhibit CD4 expression in T cells.

Conclusions:

• Upregulation of miR-221/222 in the blood of CRC patients is associated with decreased CD4+ T cell counts.
• miR-221 and miR-222 are potential sensitive biomarkers for colorectal cancer diagnosis.
• Targeting miR-221/222 offers a novel strategy for modulating CD4+ T cell populations and enhancing the tumor microenvironment for immunotherapy.